Melasma (Investigational Adjunct)
Highly investigational adjunct for refractory melasma; case reports only; sun protection, hydroquinone, tretinoin, tranexamic acid, and chemical peels remain primary.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for melasma. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for melasma is investigational.
- Какие доказательства существуют?
- Tier C (investigational). No randomized controlled trials; only anecdotal reports. Evidence-based therapy for melasma: triple combination cream (hydroquinone 4% + tretinoin 0.05% + fluocinolone 0.01%, Kligman formula), strict daily broad-spectrum SPF 50 mineral sunscreen, chemical peels (glycolic, salicylic), and tranexamic acid (oral or topical). Q-switched lasers in selected cases. PIH risk from leech application may worsen melasma in darker skin types.
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening of melasma through post-inflammatory hyperpigmentation
- Permanent dark marks or scars at bite sites, especially on the face
- Local skin infection or, rarely, Aeromonas infection from leech gut bacteria
- Allergic reaction to leech saliva (uncommon)
- Trigger of rebound hyperpigmentation after initial improvement
- Delay of evidence-based topical therapy and sun protection
- Cosmetic disfigurement that may be permanent
- Кому не следует это рассматривать
- Patients with darker Fitzpatrick skin types (IV-VI) at very high PIH risk
- Patients with active inflammatory skin disease at the planned bite site
- Pregnant patients (melasma is hormonal — leech bites add risk without addressing cause)
- Patients on anticoagulants or with severe anemia
- Patients who have not tried triple combination cream and strict sun protection
- Patients with photosensitivity or active sun-induced skin damage
- О чём спросить врача
- Have I tried Kligman's triple combination cream consistently for 12 weeks?
- Am I using a broad-spectrum mineral SPF 50 sunscreen daily?
- Have we addressed hormonal triggers (oral contraceptives, pregnancy, thyroid)?
- Am I a candidate for oral or topical tranexamic acid?
- What is the realistic risk of worsening pigmentation given my skin type?
- Are leeches from an FDA-registered supplier and used only once?
- What is the cost and is it covered by insurance? (typically not covered)
- Когда срочно обратиться за медицинской помощью
- Rapidly worsening or spreading pigmentation after treatment
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
- New scarring or permanent dark marks at bite sites
Что это НЕ означает
- This is NOT FDA-cleared for melasma.
- Anecdotal reports do NOT establish efficacy versus triple combination cream, tranexamic acid, or chemical peels.
- It does NOT mean leech therapy is appropriate for facial pigmentary conditions — PIH risk often outweighs any benefit.
- It does NOT address hormonal triggers (pregnancy, oral contraceptives) that drive melasma.
- It does NOT substitute for evidence-based topical therapy plus strict daily sun protection.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- dermatological
- ICD-10
- L81.1
- Safety tier
- medium
Evidence Summary
Melasma management per the AAD includes strict sun protection (broad-spectrum SPF 50+, iron-oxide-containing visible-light protection), topical hypopigmenting agents (hydroquinone, the Kligman trio, azelaic acid, tranexamic acid), oral tranexamic acid (off-label), chemical peels, and laser therapy (with significant relapse risk). No controlled clinical trial of leech therapy for melasma has been published; its use is investigational and mechanistic only. The hormonal and UV-driven pathophysiology of melasma is unlikely to be addressed by peripheral leech application. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Singh R et al. (2020)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Pregnancy (chloasma)
- Concurrent hormonal contraception driving hyperpigmentation (consider change)
- Active inflammatory dermatosis at proposed site
- Recent laser or chemical peel (<6 weeks)
- Tendency to post-inflammatory hyperpigmentation (treatment may worsen)
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.